Free Trial

Creative Medical Technology Q1 2024 Earnings Report

Creative Medical Technology logo
$2.07 +0.07 (+3.50%)
(As of 12/20/2024 05:51 PM ET)

Creative Medical Technology EPS Results

Actual EPS
-$0.73
Consensus EPS
-$1.15
Beat/Miss
Beat by +$0.42
One Year Ago EPS
N/A

Creative Medical Technology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Creative Medical Technology Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Creative Medical Technology Earnings Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More Creative Medical Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Creative Medical Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Creative Medical Technology and other key companies, straight to your email.

About Creative Medical Technology

Creative Medical Technology (NASDAQ:CELZ), a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

View Creative Medical Technology Profile

More Earnings Resources from MarketBeat

Upcoming Earnings